We have expanded our IP portfolio for our key technology. 

Whilst our original patent application to deliver seRNA via plasmid DNA is currently in its nationalization phase, with Japan already granting the patent and other countries expecting to do so shortly, we have last week submitted a new patent application to protect the delivery of improved seRNA as an RNA molecule.

Thus, this establishes seRNA as novel platform technology. It enables target cell selective RNA therapeutics in numerous indications and therapeutics areas and by selection of a delivery approach that is best suited for the indication we intend to target.

We have reached agreement with beniag GmbH and have exclusively in-licensed their proprietary Fusogenic Liposome technology and know-how for the delivery of RNAs in vivo.

Delivery of nucleic acids by systemic application is a key hurdle and is preventing novel therapies to be developed faster and more efficient. Fusogenic Liposomes will enable us to pre-target our seRNAs to organs and tissues of interest and thus help us to overcome this challenge. 

This will lead to the faster, more efficient development of seRNAs thereby supporting our efforts to bring seRNAs to patients in some of the most devastating diseases.